Pierre‐Yves Royer

810 total citations
17 papers, 401 citations indexed

About

Pierre‐Yves Royer is a scholar working on Neurology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Pierre‐Yves Royer has authored 17 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Neurology, 9 papers in Infectious Diseases and 4 papers in Epidemiology. Recurrent topics in Pierre‐Yves Royer's work include Long-Term Effects of COVID-19 (12 papers), COVID-19 Clinical Research Studies (9 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Pierre‐Yves Royer is often cited by papers focused on Long-Term Effects of COVID-19 (12 papers), COVID-19 Clinical Research Studies (9 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Pierre‐Yves Royer collaborates with scholars based in France, Tunisia and India. Pierre‐Yves Royer's co-authors include Timothée Klopfenstein, Vincent Gendrin, Souheil Zayet, Lynda Toko, N’dri Juliette Kadiane-Oussou, H. Zahra, Quentin Lepiller, Alix Pierron, Thierry Conrozier and Anne Lohse and has published in prestigious journals such as Emerging infectious diseases, Journal of Medical Virology and Microbes and Infection.

In The Last Decade

Pierre‐Yves Royer

16 papers receiving 387 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pierre‐Yves Royer France 10 219 219 78 51 51 17 401
Lynda Toko France 10 204 0.9× 205 0.9× 78 1.0× 51 1.0× 50 1.0× 14 385
N’dri Juliette Kadiane-Oussou France 6 176 0.8× 150 0.7× 63 0.8× 26 0.5× 45 0.9× 8 291
Max Augustin Germany 10 148 0.7× 114 0.5× 65 0.8× 19 0.4× 47 0.9× 29 389
L Suardi Italy 9 126 0.6× 71 0.3× 43 0.6× 14 0.3× 50 1.0× 17 240
Giulia Renisi Italy 7 254 1.2× 261 1.2× 12 0.2× 65 1.3× 28 0.5× 18 434
Tarek Aldabbagh Saudi Arabia 4 241 1.1× 222 1.0× 9 0.1× 54 1.1× 43 0.8× 7 354
Felix Dewald Germany 8 132 0.6× 92 0.4× 65 0.8× 17 0.3× 24 0.5× 15 269
Sean Buono United States 9 98 0.4× 27 0.1× 27 0.3× 14 0.3× 43 0.8× 12 244
Genoveva Cuesta Spain 9 126 0.6× 30 0.1× 30 0.4× 6 0.1× 36 0.7× 26 201
Andrea Smarrazzo Italy 8 138 0.6× 28 0.1× 32 0.4× 17 0.3× 46 0.9× 15 269

Countries citing papers authored by Pierre‐Yves Royer

Since Specialization
Citations

This map shows the geographic impact of Pierre‐Yves Royer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre‐Yves Royer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre‐Yves Royer more than expected).

Fields of papers citing papers by Pierre‐Yves Royer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre‐Yves Royer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre‐Yves Royer. The network helps show where Pierre‐Yves Royer may publish in the future.

Co-authorship network of co-authors of Pierre‐Yves Royer

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre‐Yves Royer. A scholar is included among the top collaborators of Pierre‐Yves Royer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre‐Yves Royer. Pierre‐Yves Royer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Klopfenstein, Timothée, Souheil Zayet, Vincent Gendrin, et al.. (2024). CRP under 130 mg/L rules out the diagnosis of Legionella pneumophila serogroup 1 (URINELLA Study). European Journal of Clinical Microbiology & Infectious Diseases. 43(6). 1051–1059.
2.
Zayet, Souheil, Timothée Klopfenstein, Vincent Gendrin, et al.. (2023). Campylobacter fetus Invasive Infections and Risks for Death, France, 2000–2021. Emerging infectious diseases. 29(11). 2 indexed citations
3.
Klopfenstein, Timothée, Vincent Gendrin, Julien Mercier, et al.. (2022). Third of patients have gustatory dysfunction 9 months after SARS-CoV-2 infection: the ANOSVID study. International Journal of Infectious Diseases. 119. 114–116. 2 indexed citations
4.
Mercier, Julien, Kévin Bouiller, Vincent Gendrin, et al.. (2022). Olfactory dysfunction in COVID‐19, new insights from a cohort of 353 patients: The ANOSVID study. Journal of Medical Virology. 94(10). 4762–4775. 9 indexed citations
5.
Zayet, Souheil, Julien Mercier, Elodie Bouvier, et al.. (2022). Asthma and Cacosmia Could Be Predictive Factors of Olfactory Dysfunction Persistence 9 Months after SARS-CoV-2 Infection: The ANOSVID Study. Life. 12(7). 929–929. 1 indexed citations
6.
Zayet, Souheil, Alix Pierron, Julie Plantin, et al.. (2021). Leclercia adecarboxylata as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing. Pathogens. 10(11). 1399–1399. 25 indexed citations
7.
Zayet, Souheil, Pierre‐Yves Royer, Lynda Toko, et al.. (2021). Recurrence of COVID-19 after recovery ? A case series in health care workers, France. Microbes and Infection. 23(4-5). 104803–104803. 9 indexed citations
8.
Klopfenstein, Timothée, Vincent Gendrin, Thierry Conrozier, et al.. (2021). Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab’s Place in COVID-19 Pneumonia. Infectious Diseases and Therapy. 10(3). 1195–1213. 14 indexed citations
9.
Puyraveau, Marc, Quentin Lepiller, Vincent Gendrin, et al.. (2021). COVEVOL: Natural Evolution at 6 Months of COVID-19. Viruses. 13(11). 2151–2151. 14 indexed citations
10.
Royer, Pierre‐Yves, et al.. (2021). Angioedema and COVID-19: A New Dermatological Manifestation?. Infectious Disease Reports. 13(1). 23–25. 2 indexed citations
11.
Zayet, Souheil, H. Zahra, Pierre‐Yves Royer, et al.. (2021). Post-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comté Hospital, France. Microorganisms. 9(8). 1719–1719. 33 indexed citations
12.
Lohse, Anne, Timothée Klopfenstein, Pierre‐Yves Royer, et al.. (2020). Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19). Microbes and Infection. 22(9). 500–503. 14 indexed citations
13.
Zayet, Souheil, N’dri Juliette Kadiane-Oussou, Quentin Lepiller, et al.. (2020). Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster. Microbes and Infection. 22(9). 481–488. 140 indexed citations
14.
Conrozier, Thierry, Anne Lohse, Jean‐Charles Balblanc, et al.. (2020). Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.. PubMed. 38(4). 742–747. 32 indexed citations
15.
Kadiane-Oussou, N’dri Juliette, Timothée Klopfenstein, Pierre‐Yves Royer, et al.. (2020). COVID-19: comparative clinical features and outcome in 114 patients with or without pneumonia (Nord Franche-Comte Hospital, France). Microbes and Infection. 22(10). 622–625. 10 indexed citations
16.
Klopfenstein, Timothée, Souheil Zayet, Anne Lohse, et al.. (2020). Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. International Journal of Infectious Diseases. 99. 491–495. 37 indexed citations
17.
Klopfenstein, Timothée, H. Zahra, N’dri Juliette Kadiane-Oussou, et al.. (2020). New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France. International Journal of Infectious Diseases. 100. 117–122. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lynda Toko Breakdown of academic impact, for papers by N’dri Juliette Kadiane-Oussou Breakdown of academic impact, for papers by Max Augustin Breakdown of academic impact, for papers by L Suardi Breakdown of academic impact, for papers by Giulia Renisi Breakdown of academic impact, for papers by Tarek Aldabbagh Breakdown of academic impact, for papers by Felix Dewald Breakdown of academic impact, for papers by Sean Buono Breakdown of academic impact, for papers by Genoveva Cuesta Breakdown of academic impact, for papers by Andrea Smarrazzo
Rankless by CCL
2026